Scrip
Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
05 November 2009
Malini Guha
Amgen's Vectibix (panitumumab) has failed to prolong overall survival in its pivotal Phase III PRIME trial testing the EGFR-targeted human monoclonal antibody as a first-line treatment in advanced colorectal cancer, although a positive trend has been seen.
Median overall survival...
Please Login to read the full article.
05 November 2009
Malini Guha
Median overall survival...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vectibix clears PFS but survival hurdle still awaits in colorectal cancer
- New analysis seeks to find mutations that predict response to Amgen's Vectibix in colorectal cancer
- Vectibix fails pivotal trial in head and neck cancer
- Vectibix recommended for colorectal cancer in Japan
FEATURES
Other Informa Features
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
